retatrutide and heart issues Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug Retatrutide and LDL Cholesterol: How

Why is this important

Type 2 diabetes was the original chronic condition for which GLP-1s were approved by the FDA in 2005

Ozempic and Mounjaro are not FDA-approved to treat obesity or for weight loss

From their beginnings as a treatment for type 2 diabetes, GLP-1 receptor agonists such as the semaglutide drugs Ozempic and Wegovy and the tirzepatide drugs Mounjaro and Zepbound have seen an explosion in use, most popularly for weight loss

To measure the insulinotropic effects of GLP-1 (7-37) in a physiologically relevant animal model, Habener reached out to his friend Gordon Weir, an endocrinologist based at the Joslin Diabetes Center and Harvard Medical School